Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase Ⅰb/Ⅱ Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10506 in Chinese Adult Participants With Insomnia Disorder

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 05 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Apr 2026 Primary endpoint has been met. (Change from baseline in the mean LPS measured by PSG on Night 13 and Night 14), according to a Shanghai Hansoh Biomedical media release.
17 Apr 2026 According to a Shanghai Hansoh Biomedical media release, study data evaluating HS-10506 will be presented at the 2026 American Academy of Neurology Annual Meeting (AAN 2026), held on April 18-22 in Chicago.
17 Apr 2026 Results presented in the Shanghai Hansoh Biomedical media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com